These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 16826310)

  • 41. Prevention of meningococcal disease.
    Woodard JL; Berman DM
    Fetal Pediatr Pathol; 2006; 25(6):311-9. PubMed ID: 17696042
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reduction in Neisseria meningitidis infection in Italy after Meningococcal C conjugate vaccine introduction: A time trend analysis of 1994-2012 series.
    de Waure C; Miglietta A; Nedovic D; Mereu G; Ricciardi W
    Hum Vaccin Immunother; 2016; 12(2):467-73. PubMed ID: 26308192
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Challenges for development of meningococcal vaccines in infants and children.
    Deasy A; Read RC
    Expert Rev Vaccines; 2011 Mar; 10(3):335-43. PubMed ID: 21434801
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serogroup B meningococcal vaccines.
    Zimmer SM; Stephens DS
    Curr Opin Investig Drugs; 2006 Aug; 7(8):733-9. PubMed ID: 16955685
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of new vaccines against meningococcal disease.
    Bröker M
    Arzneimittelforschung; 2003; 53(12):805-13. PubMed ID: 14732960
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Anti-meningococcal vaccines: diversity of vaccination policies and recommendations].
    Gendrel D
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S70-6. PubMed ID: 22883370
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Meningococcal vaccine in travelers.
    Wilder-Smith A
    Curr Opin Infect Dis; 2007 Oct; 20(5):454-60. PubMed ID: 17762777
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis.
    Patel M; Lee CK
    Cochrane Database Syst Rev; 2005 Jan; (1):CD001093. PubMed ID: 15674874
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Meningococcal vaccination in pregnancy.
    Abu Raya B; Sadarangani M
    Hum Vaccin Immunother; 2018 May; 14(5):1188-1196. PubMed ID: 29485347
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Salivary and Serum Antibody Response Against Neisseria meningitidis After Vaccination With Conjugate Polysaccharide Vaccines in Ethiopian Volunteers.
    Bårnes GK; Workalemahu B; Kristiansen PA; Beyene D; Merdekios B; Fissiha P; Aseffa A; Caugant DA; Naess LM
    Scand J Immunol; 2016 Aug; 84(2):118-29. PubMed ID: 27219622
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Meningococcal conjugate vaccines.
    Pichichero ME
    Expert Opin Biol Ther; 2005 Nov; 5(11):1475-89. PubMed ID: 16255651
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined effect of PCV10 and meningococcal C conjugate vaccination on meningitis mortality among children under five years of age in Brazil.
    Bierrenbach AL; Minamisava R; Alencar AP; Alencar GP; Andrade AL
    Hum Vaccin Immunother; 2018 May; 14(5):1138-1145. PubMed ID: 29068749
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Global epidemiology of meningococcal disease and vaccine efficacy.
    Pollard AJ
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S274-9. PubMed ID: 15597069
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Meningococcal disease before and after the introduction of meningococcal serogroup C conjugate vaccine. Federal District, Brazil.
    Tauil Mde C; Carvalho CS; Vieira AC; Waldman EA
    Braz J Infect Dis; 2014; 18(4):379-86. PubMed ID: 24698710
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Critical analysis of old and new vaccines against N. meningitidis serogroup C, considering the meningococcal disease epidemiology in Brazil.
    Bricks LF
    Rev Hosp Clin Fac Med Sao Paulo; 2003; 58(4):231-40. PubMed ID: 14534678
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identifying optimal vaccination strategies for serogroup A Neisseria meningitidis conjugate vaccine in the African meningitis belt.
    Tartof S; Cohn A; Tarbangdo F; Djingarey MH; Messonnier N; Clark TA; Kambou JL; Novak R; Diomandé FV; Medah I; Jackson ML
    PLoS One; 2013; 8(5):e63605. PubMed ID: 23671685
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The impact of aggregating serogroups in dynamic models of Neisseria meningitidis transmission.
    Poore KD; Bauch CT
    BMC Infect Dis; 2015 Jul; 15():300. PubMed ID: 26223223
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of pneumococcal conjugate vaccine on the prevention of invasive pneumococcal diseases.
    Bricks LF; Berezin E
    J Pediatr (Rio J); 2006 Jul; 82(3 Suppl):S67-74. PubMed ID: 16721440
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity.
    Kristiansen PA; Diomandé F; Ba AK; Sanou I; Ouédraogo AS; Ouédraogo R; Sangaré L; Kandolo D; Aké F; Saga IM; Clark TA; Misegades L; Martin SW; Thomas JD; Tiendrebeogo SR; Hassan-King M; Djingarey MH; Messonnier NE; Préziosi MP; Laforce FM; Caugant DA
    Clin Infect Dis; 2013 Feb; 56(3):354-63. PubMed ID: 23087396
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness of expanding childhood routine immunization against Neisseria meningitidis serogroups C, W and Y with a quadrivalent conjugate vaccine in the African meningitis belt.
    Kuznik A; Iliyasu G; Lamorde M; Mahmud M; Musa BM; Nashabaru I; Obaro S; Mohammed I; Habib AG
    PLoS One; 2017; 12(11):e0188595. PubMed ID: 29190699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.